Loading…
Recently listed clinical-stage pharmaceutical company; specific pipeline and disease focus not confidently known.
Recently listed clinical-stage pharmaceutical company; specific pipeline and disease focus not confidently known.
Moat: none
Employees: 106
Size Definium Therapeutics (DFTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $4.47B, the 1269th largest of 3,117 United States companies the cockpit tracks. Shares closed at $33.27 on 6 Nov 2026.
Performance Over six months the shares gained 50.9%, against +3.3% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 20 in its peer set.
Short interest Short interest is 7.5% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $0 | $0 | -$527,000 | -$3.16M | -$3.22M |
| EBITDA | -$228M | -$166M | -$103M | -$90.7M | -$63.1M |
| Net income | -$354M | -$184M | -$109M | -$95.7M | -$56.8M |
| Free cash flow | -$167M | -$132M | -$79.1M | -$64.4M | -$50.1M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Total debt | $36.5M | $40.6M | $21.9M | $14.1M | $72,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DFTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.7% | +6.5% | 8th lowest of 20 |
| 6-month return | +50.9% | +3.3% | highest of 20 |
| Distance from 52-week high | -33.1% | -28.5% | 10th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Definium Therapeutics DFTX | United States | $4.47B | +51% | n/a | n/a | n/a | n/a | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $4.47B | -34% | +227% | 74% | 6.5× | 3.3% | +45.1% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.47B | +33% | +21% | 16% | 4.3× | 14.9% | +12.7% |
| Camurus CAMX.ST | Sweden | $4.52B | +47% | 0% | 37% | 17.8× | 10.4% | +46.5% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.53B | +2% | +12% | 33% | 9.8× | 25.2% | +5.5% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $4.53B | -17% | +60% | -4% | 3.0× | n/a | n/a |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.56B | -23% | +6% | 3% | 0.6× | 0.7% | +4.0% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.37B | +7% | +25% | 25% | 6.6× | 23.8% | +13.8% |
| HanmiPharm 128940.KS | South Korea | $4.36B | +2% | +14% | 16% | 3.5× | 5.0% | +7.5% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.71B | +3% | -3% | 16% | 1.6× | -6.8% | +3.0% |
| Travere Therapeutics TVTX | United States | $4.76B | +16% | +49% | -3% | 7.5× | 16.7% | +19.9% |
| Novast Laboratories 301569.SZ | China | $4.82B | n/a | +3% | 27% | 34.4× | 42.6% | +3.1% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 5.6× | 17.8% | -5.8% |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $4.08B | -39% | +36% | -14% | 9.6× | n/a | n/a |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 2.8× | -11.5% | +0.3% |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 2.4× | 20.2% | +6.2% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 3.0× | n/a | n/a |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 8.6× | 0.7% | +192.5% |
| Erasca ERAS | United States | $5.04B | +42% | n/a | n/a | n/a | n/a | n/a |
| SKBP 326030.KS | South Korea | $5.12B | -11% | +39% | 35% | 8.1× | 0.5% | +93.6% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 4.5× | 1.5% | +12.1% |